133 216

Cited 13 times in

Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy

 Min Kyu Kang  ;  Dongryul Oh  ;  Kwan Ho Cho  ;  Sung Ho Moon  ;  Hong-Gyun Wu  ;  Dae-Seog Heo  ;  Yong Chan Ahn  ;  Keunchil Park  ;  Hyo Jung Park  ;  Jun Su Park  ;  Ki Chang Keum  ;  Jihye Cha  ;  Jun Won Kim  ;  Yeon-Sil Kim  ;  Jin Hyoung Kang  ;  Young-Taek Oh  ;  Ji-Yoon Kim  ;  Sung Hwan Kim  ;  Jin-Hee Kim  ;  Chang Geol Lee 
 CANCER RESEARCH AND TREATMENT, Vol.47(4) : 871-878, 2015 
Journal Title
Issue Date
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use* ; Chemotherapy, Adjuvant ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Neoplasms/classification ; Nasopharyngeal Neoplasms/drug therapy* ; Nasopharyngeal Neoplasms/radiotherapy* ; Neoadjuvant Therapy ; Neoplasm Staging ; Prognosis ; Survival Analysis
Chemoradiotherapy ; Chemotherapy ; Nasopharyngeal carcinoma ; Radiotherapy
PURPOSE: To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. MATERIALS AND METHODS: From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy). RESULTS: Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last follow-up, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. CONCLUSION: Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.
Files in This Item:
T201504031.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Keum, Ki Chang(금기창) ORCID logo https://orcid.org/0000-0003-4123-7998
Kim, Jun Won(김준원) ORCID logo https://orcid.org/0000-0003-1358-364X
Lee, Chang Geol(이창걸) ORCID logo https://orcid.org/0000-0002-8702-881X
Cha, Ji Hye(차지혜)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.